Polygenic risk score: the potential role in the management of systemic lupus erythematosus

Chi Chiu Mok
DOI: https://doi.org/10.1136/rmdopen-2024-004156
2024-05-04
RMD Open
Abstract:Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease characterised by substantial clinical and serological heterogeneity, leading to a high variability in the disease course, treatment response and prognosis in different patients. Although the exact pathoaetiology of SLE remains elusive, complex interaction among genetic, epigenetic and environmental factors such as ultraviolet light, hormones, drugs and viral infections is probably involved.1 Genetic risk alleles may assist SLE management in various ways. These potentially include: (1) identification of individuals who are more susceptible to the disease development and thus help in differentiation of SLE from other autoimmune diseases during the diagnostic process; (2) stratification of patients according to disease severity/prognosis for clinical trials and treatment decisions; (3) prediction of response and adverse effects to drug therapies; and (4) identification of molecular targets for pharmacological development. Over the past two decades, genome-wide association studies (GWAS) have identified more than 200 risk loci in SLE, which underscores it is a complex polygenic disease. Guga et al 2 summarised 2 human leucocyte antigen (HLA), 127 non-HLA and 2 X chromosome novel SLE risk loci from GWAS published in the past 5 years, with 75 of the non-HLA loci being Asian specific and five being European specific. However, as more than 90% of these risk alleles are located within the non-coding regions, the functional significance of the genetic variants is poorly understood.3 Detection of the true causal variants within a given risk locus ...
rheumatology
What problem does this paper attempt to address?